Immix Biopharma (IMMX) Current Assets (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Current Assets data on file, last reported at $92.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 449.93% year-over-year to $92.3 million; the trailing twelve-month figure through Mar 2026 stood at $92.3 million (up 449.93% YoY), and the FY2025 full-year result was $101.2 million, up 401.23% from the prior year.
• Current Assets retreated to $92.3 million in Q1 2026, from $101.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $101.2 million in Q4 2025 to a low of $12.3 million in Q2 2025.
• A 5-year average of $28.5 million and a median of $19.8 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets sank 54.9% in 2025 and jumped 449.93% in 2026, its largest moves.
• Tracing IMMX's Current Assets over 5 years: stood at $14.9 million in 2022, then soared by 32.82% to $19.8 million in 2023, then advanced by 2.07% to $20.2 million in 2024, then surged by 401.23% to $101.2 million in 2025, then fell by 8.85% to $92.3 million in 2026.
• Business Quant data shows IMMX's Current Assets at $92.3 million in Q1 2026, $101.2 million in Q4 2025, and $16.6 million in Q3 2025.